HC Wainwright reiterates Buy on Corcept Therapeutics, $165 target
HC Wainwright & Co. reiterated a Buy rating on Corcept Therapeutics and set a $165.00 price target, implying 43.7% upside versus the Sep 17 close of $114.86.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.